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Perspectives
Although Di Zenzo et al. (2010) demon-
strated convincingly that intramolecular 
epitope spreading occurs in BPAG2, 
many questions remain. The first is why 
patients with bullous pemphigoid pref-
erentially develop IgG autoantibod-
ies to epitopes on the NC16a domain 
of BPAG2. Second, why do autoanti-
bodies in bullous pemphigoid react 
with epitopes in the NC16a domain 
of BPAG2, whereas autoantibodies in 
anti-BP180–type mucous membrane 
pemphigoid react with epitopes in the 
C-terminal domain? More important, 
how do the antibodies directed against 
these distinct domains of BPAG2 result 
in different clinical features (i.e., large, 
tense skin blisters in bullous pemphig-
oid and predominant erosive mucosal 
lesions in anti-BP180-type mucous 
membrane pemphigoid)? Why do IgA 
antibodies in lamina lucida–type lin-
ear IgA bullous dermatosis react with 
specific epitopes in 120- and 97-kDa 
linear IgA bullous dermatosis (LAD)-1 
antigens produced from 180-kDa intact 
BPAG2 by proteolytic processing (Nie 
et al., 2000)? Future studies should 
unravel the mechanisms by which the 
hidden epitope in intact 180-kDa mol-
ecule (intact BPAG2) is exposed in 
linear IgA bullous dermatosis to autoan-
tibodies against the 120- and 97-kDa 
LAD-1 antigens.
Finally, and perhaps most important, 
we do not know yet why the develop-
ment of antibodies against ICD epitopes 
in human BPAG2 correlated with skin-
graft loss. The relevance of this phenom-
enon to autoimmune bullous diseases 
remains to be determined.
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More or Less: Copy Number 
Alterations in Mycosis Fungoides
William M. Lin1 and Michael Girardi1
mycosis fungoides (mF) is the most common form of cutaneous t-cell lymphoma 
(ctcL), a heterogeneous group of non-Hodgkin’s lymphomas of skin-homing 
t cells. mF may vary from limited patchy skin disease to extensive cutaneous 
plaque and tumor involvement to extracutaneous compartments of blood, 
lymph nodes, and viscera. advances in genomic technologies have enabled the 
increasing characterization of genetic alterations in this malignancy; using this 
technology, investigators hope to understand mF’s variable behavior and patho-
genesis. In this issue, Salgado et al. identify regions of genomic Dna alterations 
from 41 mF samples and report associations with prognosis.
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Clinical Implications
•  Epitope spreading is the sequential development of new antibodies against 
seemingly less accessible regions of target proteins in autoimmunity.
•  The identification of mechanisms of epitope spreading in the 
immunobullous diseases may lead to novel therapies that limit the process 
of spreading.
•  Because of accessibility, the analysis of epitope spreading in skin disease 
may provide insight into pathogenic mechanisms in systemic autoimmune 
diseases and transplantation immunity.
In recognition that cancer is fun-
damentally dependent on genetic 
alterations (Vogelstein and Kinzler, 
2004), the number of genomic 
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Genetic modifiers of prognosis
Much of the difficulty in translating 
genomic data to biologic insight lies 
in the lack of sufficient phenotypic 
data, and it is thus informative that 
Salgado et al. (2010) collected sur-
vival data. Together, DNA changes 
that correlate with decreased sur-
vival suggest that the genes within a 
given region are, at least, associated 
with oncogenesis, but they may also 
be implicated in disease progression. 
Salgado et al. identify three regions 
associated with a poorer progno-
sis. van Doorn et al. (2009) reported 
that the deletion of 9p21 predicted 
decreased survival, and Salgado et al. 
narrow this region to 9p21.3, which 
includes the known tumor suppres-
sor genes CDKN2A, CDKN2B, and 
MTAP. Given past reports of CDKN2A 
being hypermethylated (Navas et al., 
2002), the current CGH data support 
the notion that CDKN2A functions as 
a tumor suppressor in MF.
Salgado and colleagues similarly 
confirm the association of 8q ampli-
fication with poorer prognosis, as 
first reported by Fischer et al. (2004). 
Instead of 8q24.3, as reported by van 
Doorn et al. (2009), however, Salgado 
et al. found that gain of 8q24.21, 
which includes the oncogene MYC, 
correlates with decreased survival. 
With a high-level amplification of the 
region including MYC in two patients 
(Salgado et al., 2010) and an indepen-
dent report that MYC is also one of 
the most commonly amplified genes 
in Sézary syndrome (Vermeer et al., 
2008), these findings lend support to 
the importance of MYC and suggest 
its primary oncogenic role in CTCL 
progression.
samples provides a whole-genome 
view of a cancer while allowing the 
focused identification of commonly 
amplified or deleted regions harboring 
potential oncogenes or tumor sup-
pressors, respectively. Because large 
regions of chromosomes can often be 
gained or lost in a particular sample, it 
is often through increased sample size 
that a “minimal common region” of 
overlap is defined, thereby narrowing 
a region to its true gene target. Finer 
resolution of genomic data is also 
important, and increases in genomic 
coverage have improved detection 
from chromosomal or arm-level gains 
and losses down to cytoband changes. 
Together with improved algorithms, 
these analyses may allow investigators 
to narrow regions of genetic alteration 
down to single genes.
The clinical heterogeneity of CTCL 
patients and the relative infrequency 
of the disease have often been cited as 
impediments to conducting genomic 
studies in this malignancy (Karenko et 
al., 2007). These factors, compounded 
by challenges in isolating and culturing 
tumor cells, have slowed investigators’ 
ability to define recurrent mutations 
that may be critical in CTCL onco-
genesis relative to other hematological 
malignancies or melanoma (Lin et al., 
2008). The data set of Salgado et al. 
(2010) represents an admirably large 
group of similar patient samples. By 
comparing these data with those of 
other published reports, consensus 
minimal common regions of DNA 
copy gain and loss in MF can be 
elucidated, although even larger and 
higher-resolution studies will be nec-
essary to further focus analyses and 
define the primary genes in CTCL.
cutaneous T-cell lymphoma (CTCL) 
studies has rapidly increased, in the 
hope of shedding light on its poorly 
understood genetic basis (Karenko 
et al., 2007). Knowledge of the criti-
cal chromosomal abnormalities and 
genetic mutations involved in mycosis 
fungoides (MF) may provide insight 
into its pathogenesis, and a finer 
molecular classification may lead to 
the identification of novel therapeutic 
targets. Advances in genomic techno-
logy have facilitated CTCL charac-
terization, and the resulting studies 
have begun to identify some of the 
major genes that may be involved in 
CTCL development and progression 
(Mao et al., 2002; Fischer et al., 2004; 
Prochazkova et al., 2007; Carbone 
et al., 2008; van Doorn et al., 2009; 
Vermeer et al., 2009).
The study by Salgado and col-
leagues (2010, this issue) enhances 
our understanding of MF at the 
genomic level. First, the investiga-
tors identified regions of DNA copy 
number gains and losses in 41 skin 
biopsies of tumor–stage MF with 
Agilent 60-mer 44K oligonucleotide 
array comparative genomic hybrid-
ization (“array CGH”). Second, they 
used the number of DNA alterations, 
DNA breaks, and homozygous dele-
tions/high-level amplifications as 
an indicator of genomic instability 
and observed decreased survival in 
patients with high genomic instability. 
Third, they determined three specific 
regions of DNA alteration—9p21.3, 
8q24.21, and 10q26qter—as genetic 
modifiers of prognosis. Finally, and 
perhaps most important, they have 
submitted to the field the largest and 
highest-resolution data set for MF to 
date.
copy number landscape
Comparative genomic hybridization 
(CGH) enables the assessment of 
genomic changes in DNA copy 
number by comparing the degree 
of hybridization of a labeled probe 
in cancerous tissues against normal 
samples. Advances on this basic con-
cept such as array CGH have allowed 
a markedly increased resolution in 
DNA copy number. Thus, generating 
CGH copy number data from tumor 
Clinical Implications
•  Interpreting the role of acquired genetic mutations requires  
a full clinical characterization of patients with CTCL, a task  
for astute clinicians.
•  Instability in the integrity of DNA is an important characteristic  
of the malignant cells in CTCL.
•  We are reaching the point at which the identification of genetic 
mutations in malignant T cells may predict the outcome of patients 
with CTCL.
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Finally, Salgado et al. identify the 
loss of 10q26qter, which narrows 
the region from 10q, as reported by 
Fischer et al. (2004). Included within 
this deletion are two tumor suppres-
sors, MGMT and EBF3, nominated 
by Salgado et al.  as candidates. 
Particularly with reports of MGMT 
methylation-mediated inactivation in a 
subset of CTCL (Gallardo et al., 2004), 
further studies must validate and dis-
sect its function in MF. Additional 
genetic markers reported to decrease 
prognosis include gain of 1q21–1q22 
(van Doorn et al., 2009). Also, Fischer 
et al. (2004) determined that the 
loss of 6q and loss of 13q correlated 
with decreased survival; however, it 
is important to note that other CTCL 
subtypes were included in that study. 
Although meta-analyses of combined 
genomic and survival data will help 
confirm these findings, along with the 
addition of new cohorts, currently, loss 
of 9p21.3, gain of 8q24.21, and loss 
of 10q26qter appear to be the three 
primary loci that predict poor survival 
in MF. The likely roles of CDKN2A, 
CDKN2B, MTAP, MYC, and MGMT in 
MF merit further study, and functional 
validation will better delineate their 
importance in this malignancy.
Genomic instability
Genomic instability is typically divid-
ed into two classes: chromosomal 
instability and microsatellite instabil-
ity (Aguilera and Gomez-Gonzalez, 
2008). In assessing genomic instabil-
ity, Salgado et al. (2010) define two 
groups of samples: high genomic 
instability and low genomic instabil-
ity, based on: (i) number of DNA copy 
number changes (<5 vs. >5), (ii) the 
presence of high-level copy number 
changes (presence vs. absence), and 
(iii) DNA breaks (<3 vs. >10). The 
observation that patients with more 
DNA copy number changes (a gross 
marker of chromosomal instability) 
have poorer survival confirms a similar 
analysis done by Fischer et al. (2004) 
and raises the following questions: 
What are the regulators of genomic 
stability in CTCL and how might they 
be maintained? Moreover, is genom-
ic instability an early or late genetic 
event? The authors note a correlation 
between genomic instability and gain 
of 7q, yet it is unclear whether this is 
a cause or a consequence. Focused 
genomic analyses, particularly with 
other types of mutation data such as 
gene expression, of known regulator 
genes of genomic stability (compiled 
by Aguilera and Gomez-Gonzalez, 
2008), coupled with functional stud-
ies, may help address these questions.
Future directions
Evolutionary selection pressures 
in tumors manifest themselves in 
many mutations not limited to DNA 
copy number gains/losses, loss-of-
heterozygosity, miRNA-related gene 
expression changes, epigenetic modi-
fications, translocations, and point 
mutations. In this issue, Salgado et 
al. contribute to our understanding 
of DNA copy number changes in MF, 
narrowing in on and confirming many 
suspected gene targets. However, 
going forward, analyzing one type 
of mutation in the setting of mul-
tiple levels of cellular dysregulation 
impairs our ability to comprehend 
the full picture. Although we are still 
defining the key genes in CTCL, its 
primary biological pathways and how 
these mutations interact with one 
another to promote carcinogenesis 
remain relatively unexplored. These 
efforts will likely rely on modeling 
many kinds of mutations—because if 
a gene is critical for pathogenesis, a 
cancer cell will probably find some 
way to mutate it. Equally important to 
future analyses will be the collection 
of full clinical data on these patients. 
Together with functional experimen-
tation, genomics integrated with sta-
tistical algorithms should enable the 
discovery of new therapeutic targets 
while elucidating the mechanisms that 
underlie transformation. Furthermore, 
an understanding of the genetic basis 
of CTCL may help explain its immu-
nomodulatory nature. This is indeed 
an exciting time in CTCL genetics, 
with tremendous potential for a better 
understanding of T-cell malignancies 
and improved clinical care.
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